Drug interaction of plasma protein binding
... Excretion of Drug The process in which of their prototype and their metabolites transferred from the internal to the external environment of body. The pathways of excretion includes: renal peptic, respiratory and milk excretion. ...
... Excretion of Drug The process in which of their prototype and their metabolites transferred from the internal to the external environment of body. The pathways of excretion includes: renal peptic, respiratory and milk excretion. ...
Anti-inflammatory & Pain
... • NSAIDs work by inhibiting cyclooxygenase, which has two forms – Cox-1 is involved with the stomach – Cox-2 is involved with inflammation ...
... • NSAIDs work by inhibiting cyclooxygenase, which has two forms – Cox-1 is involved with the stomach – Cox-2 is involved with inflammation ...
MUSCARINIC RECEPTOR ANTAGONISTS:
... absorption of swallowed dose, therefore minimizing the systemic effects. a scopolamine derivative. ...
... absorption of swallowed dose, therefore minimizing the systemic effects. a scopolamine derivative. ...
Prodrugs - ISpatula
... • Two important points: 1. The prodrug should be effectively converted to the active form once absorbed in the blood. 2. Cleavable groups are non toxic. ...
... • Two important points: 1. The prodrug should be effectively converted to the active form once absorbed in the blood. 2. Cleavable groups are non toxic. ...
Rational therapy for vomiting in dogs and cats
... Side effects: As for famotidine, requires dose reduction in renal failure (shown in humans). Unlike cimetidine, no clinically significant P450 enzyme inhibition with ranitidine at therapeutic dosages. Rapid IV infusion may cause hypotension. Omeprazole (Prilosec; Gastrogard): H+/K+ ATPase pu ...
... Side effects: As for famotidine, requires dose reduction in renal failure (shown in humans). Unlike cimetidine, no clinically significant P450 enzyme inhibition with ranitidine at therapeutic dosages. Rapid IV infusion may cause hypotension. Omeprazole (Prilosec; Gastrogard): H+/K+ ATPase pu ...
Information about Intrathecal Baclofen Pumps
... hour § Flex dosing = boluses of baclofen can be programmed at regular intervals o There are two pump sizes, 20 and 40 ml reservoirs o Concentrations: Lioresal (baclofen) comes in 500 and 2000 mcg/ml. Competitor Gablofen comes also in 1000 mcg/ml, though we do not have patients with this concentrati ...
... hour § Flex dosing = boluses of baclofen can be programmed at regular intervals o There are two pump sizes, 20 and 40 ml reservoirs o Concentrations: Lioresal (baclofen) comes in 500 and 2000 mcg/ml. Competitor Gablofen comes also in 1000 mcg/ml, though we do not have patients with this concentrati ...
PHYSICo chemicaL PROPERTIES
... (metabolized). The substances that result from metabolism (metabolites) may be inactive, or they may be similar to or different from the original drug in therapeutic activity or toxicity. Some drugs, called prodrugs, are administered in an inactive form, which is metabolized into an active form. ...
... (metabolized). The substances that result from metabolism (metabolites) may be inactive, or they may be similar to or different from the original drug in therapeutic activity or toxicity. Some drugs, called prodrugs, are administered in an inactive form, which is metabolized into an active form. ...
Esters and amides of hexanoic acid substituted with
... of drugs and long-term therapy from a single dose, avoid the hepatic first-pass metabolism associated with oral administration and allow easy termination of drug input. The role of chemical TPEs is to reversibly alter the barrier properties of the stratum corneum (SC), which is the outermost layer o ...
... of drugs and long-term therapy from a single dose, avoid the hepatic first-pass metabolism associated with oral administration and allow easy termination of drug input. The role of chemical TPEs is to reversibly alter the barrier properties of the stratum corneum (SC), which is the outermost layer o ...
8th Lecture 1433
... * Two drugs may have affinity for plasma protein binding sites, thus compete with each ...
... * Two drugs may have affinity for plasma protein binding sites, thus compete with each ...
Review questions from 2003-2014 IB exams for option D Medicine
... effect of these drugs on humans. Identify the stimulant responsible for the addiction to smoking tobacco List three physiological effects of stimulants Name the type of drug that increases mental alertness Explain the term sympathomimetic drug Identify 2 structural differences between amphetamine an ...
... effect of these drugs on humans. Identify the stimulant responsible for the addiction to smoking tobacco List three physiological effects of stimulants Name the type of drug that increases mental alertness Explain the term sympathomimetic drug Identify 2 structural differences between amphetamine an ...
Synthesis and degradation characteristics of salicylic acid
... The degradation pro"le re#ects the relative rates of bond hydrolysis*upon cleavage of the aromatic anhydride bonds, the newly generated carboxylic acids acidcatalyze hydrolysis of the remaining ester bonds. At pH 10, there is a lag time of &10 h, then degradation continues over a 38 h time period (F ...
... The degradation pro"le re#ects the relative rates of bond hydrolysis*upon cleavage of the aromatic anhydride bonds, the newly generated carboxylic acids acidcatalyze hydrolysis of the remaining ester bonds. At pH 10, there is a lag time of &10 h, then degradation continues over a 38 h time period (F ...
Drug Interactions Every Health Care Provider Should Know
... clopidogrel and a PPI reduces the antiplatelet effects of clopidogrel … It is not established that changes in these surrogate endpoints translate into clinically meaningful differences” ...
... clopidogrel and a PPI reduces the antiplatelet effects of clopidogrel … It is not established that changes in these surrogate endpoints translate into clinically meaningful differences” ...
No Slide Title
... •drug interactions (ampicillin, thiazides, mercaptopurine, azathioprine) •death ...
... •drug interactions (ampicillin, thiazides, mercaptopurine, azathioprine) •death ...
2nd T. 6th L. Updated - Home - KSU Faculty Member websites
... Coxibs were developed in an attempt to inhibit PG synthesis by the COX-2 isoenzyme induced at sites of inflammation without affecting the action of the constitutively active "housekeeping" COX-1 isoenzyme found in the GIT, kidneys, and platelets Coxibs selectively bind to and block the active si ...
... Coxibs were developed in an attempt to inhibit PG synthesis by the COX-2 isoenzyme induced at sites of inflammation without affecting the action of the constitutively active "housekeeping" COX-1 isoenzyme found in the GIT, kidneys, and platelets Coxibs selectively bind to and block the active si ...
Tranexamic Acid in Gynaecology & Obstetrics
... Tranexamic acid should be used with caution in: the elderly, children aged under 15 years with heavy or prolonged menstrual periods (menorrhagia), kidney disease, patients with blood in their urine, history of uncontrollable bleeding, pregnancy and breastfeeding, patients with the blood clotting dis ...
... Tranexamic acid should be used with caution in: the elderly, children aged under 15 years with heavy or prolonged menstrual periods (menorrhagia), kidney disease, patients with blood in their urine, history of uncontrollable bleeding, pregnancy and breastfeeding, patients with the blood clotting dis ...
Chapter 21 Antimicrobial medications
... being assembled to form glycan chains. By doing so it blocks the production of peptidoglycan. They do not cross the outer membrane of gram – bacteria so they are resistant. Vancomycin must be ...
... being assembled to form glycan chains. By doing so it blocks the production of peptidoglycan. They do not cross the outer membrane of gram – bacteria so they are resistant. Vancomycin must be ...
Lec.7-311-1
... • Strategies designed to target drugs to particular cells or tissues are likely to lead to safer drugs with fewer side effects. • Drugs can be linked to amino acids or nucleic acid bases to target them against fast-growing and rapidly divided cells. • Drugs can be targeted to the GIT by making them ...
... • Strategies designed to target drugs to particular cells or tissues are likely to lead to safer drugs with fewer side effects. • Drugs can be linked to amino acids or nucleic acid bases to target them against fast-growing and rapidly divided cells. • Drugs can be targeted to the GIT by making them ...
agenda
... Shorter half-life than above drugs so less damaging but also shorter time it’s effective. Can be “stacked” with above drugs for USEF showing if proper documentation filed (until December 2011). Labeled IV only but given IM as well. Many drugs sound and “look” alike though can be greatly different us ...
... Shorter half-life than above drugs so less damaging but also shorter time it’s effective. Can be “stacked” with above drugs for USEF showing if proper documentation filed (until December 2011). Labeled IV only but given IM as well. Many drugs sound and “look” alike though can be greatly different us ...
Clinical Study of ‘Triphala’ – A Well Known Phytomedicine from India R A
... cebo), group II and III were treated with Marketed Triphala M1 and M2. Group IV was treated with Triphala (IH), at the dose of 2.5 g twice daily for 1 month. Weekly observations were recorded as per proforma to assess the effect of treatment. The effectiveness of treatment was judged on the basis of ...
... cebo), group II and III were treated with Marketed Triphala M1 and M2. Group IV was treated with Triphala (IH), at the dose of 2.5 g twice daily for 1 month. Weekly observations were recorded as per proforma to assess the effect of treatment. The effectiveness of treatment was judged on the basis of ...
Year 2 Drug Table – ST
... lungs. 85% metabolised in liver, 15% Gut Oral, absorbed quickly. Delayed Effect for 12-16hrs. t½=4-5days. 99.99% Plasma protein bound, hepatic metabolism by CYP450. Poor oral absorption. Given S.C./ I.V. short t½. Saturation kinetics. LMWH has longer t½ and no saturation kinetics. ...
... lungs. 85% metabolised in liver, 15% Gut Oral, absorbed quickly. Delayed Effect for 12-16hrs. t½=4-5days. 99.99% Plasma protein bound, hepatic metabolism by CYP450. Poor oral absorption. Given S.C./ I.V. short t½. Saturation kinetics. LMWH has longer t½ and no saturation kinetics. ...
Lecture 14
... in the absence of GABA) => increased inhibition of the CNS (also block glutamate receptors) High risk of dependence (severe withdrawal symptoms) Strong depressent activity on the CNS => anesthesia At higher doses respiratory (inhibit hypoxic and CO2 response of chemoreceptors) and cardiovascular dep ...
... in the absence of GABA) => increased inhibition of the CNS (also block glutamate receptors) High risk of dependence (severe withdrawal symptoms) Strong depressent activity on the CNS => anesthesia At higher doses respiratory (inhibit hypoxic and CO2 response of chemoreceptors) and cardiovascular dep ...
Nonsteroidal Anti- Inflammatory Drugs analgesic, anti
... aggregation depend on the pharmacokinetic profiles of the agents. After administration of a single dose of aspirin, platelet aggregation is impaired for up to 4 days, until new platelets enter the circulation in sufficient numbers. ...
... aggregation depend on the pharmacokinetic profiles of the agents. After administration of a single dose of aspirin, platelet aggregation is impaired for up to 4 days, until new platelets enter the circulation in sufficient numbers. ...
HIGHLIGHTS OF PRESCRIBING INFORMATION Clostridium difficile
... Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. In most patients, treatment of hypomagnesemia required magnesium re ...
... Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. In most patients, treatment of hypomagnesemia required magnesium re ...
Discovery and development of proton pump inhibitors
Proton pump inhibitors (PPIs) block the gastric hydrogen potassium ATPase (H+,K+-ATPase) and inhibit gastric acid secretion. These drugs have emerged as the treatment of choice for acid-related diseases, including gastroesophageal reflux disease (GERD) and peptic ulcer disease.PPIs also can bind to other types of proton pumps such as those that occur in cancer cells and are finding applications in the reduction of cancer cell acid efflux and reduction of chemotherapy drug resistance.